Total: 32 results found.

Search for:
Search Only:

Page 1 of 2

1. PET imaging could lead to better care for neuroendocrine cancer ...
(In the News)
A method of molecular imaging that pinpoints hormonally active tissues in the body could change the course of treatment for a remarkable number of neuroendocrine cancer patients, say researchers at ...
Created on 14 June 2012
2. Lutathera Approved in the US
(News)
1/26/18 - Advanced Accelerator Applications (AAA) Receives FDA Approval of Lutetium (177Lu) Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine AAA announced that the Federal Drug Administration ...
Created on 27 June 2018
3. Lutathera Approved in the European Union
(News)
Advanced Accelerator Applications (AAA) Receives European Approval of Lutetium (177Lu) Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine AAA announced on September 29, 2017 that the ...
Created on 02 October 2017
4. J. Reynolds - PRRT Bad Berka
(Bad Berka)
...  For background information only, I was diagnosed with neuroendocrine cancer (Gastrinoma) with extensive liver metastasis at the age of 44. Like most NET patients, the diagnosis was made late and other ...
Created on 01 March 2017
5. New Articles On PRRT
(In the News)
New articles have been added to our file section. Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths. Vikas Prasad & Lisa Bodei & Mark ...
Created on 18 August 2014
6. 2014 SNMMI Patient Education Day
(News)
...  care management. The afternoon concluded with breakout sessions focused on hot topics in colon cancer, prostate cancer, thyroid diseases, and neuroendocrine tumors. The total number of attendees was 12 ...
Created on 18 August 2014
7. Updates from the Ga68 Working Group
(News)
Ga-68-labeled somatostatin analogs are important imaging agents to detect and manage neuroendocrine tumors (NETs). The SNMMI formed the 68Ga Users Group to advance the use of these imaging agents in the ...
Created on 18 August 2014
8. Update to a Solider Story
(Bad Berka)
...  His condition remains “Stabilized and partial remission noted.” It was also in Bad Berka where Dan met a team associated with Dr. Eric H Liu, M.D. from Vanderbilt Neuroendocrine Center, visiting Ge ...
Created on 26 February 2014
9. Becca H
(Rotterdam)
PRRT at Erasmus Medical Center, Rotterdam, The Netherlands (aka Holland), 2013 Dec2013 You and your oncologist have determined that PRRT (Lutetium 177) treatments are the best option for your neuroendocrine ...
Created on 26 February 2014
10. Ga68 - Orphan Drug Announcement
(In the News)
BREAKING NEWS – the radiopharmaceutical Gallium-68 (DOTA0-hel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the US Food and Drug Administration (FDA) for the management of neuroendocrine ...
Created on 20 November 2013
11. Pre Second World GA68 Congress Publication
(Conferences)
...   Original Articles Ga-68 DOTATATE PET/CT in Neuroendocrine Tumors: Initial Experience   Bhagwant Rai Mittal, Kanhaiyalal Agrawal, Jaya Shukla, Anish Bhattacharya, Baljinder Singh, Ashwan ...
Created on 11 February 2013
12. SNM 2012 Image of the Year: Bi-213-DOTATOC for a New Treatment for GEP-NET Tumors Resistant to Standard Therapies:
(In the News)
Miami Beach, Fla. – The Society of Nuclear Medicine's (SNM) 2012 Image of the Year illustrates the effectiveness of Bi-213-DOTATOC for the peptide receptor alpha-therapy of gastroenteropancreatic neuroendocrin ...
Created on 20 June 2012
13. First World Congress of Ga-68 and PRRNT - an Overwhelming Success
(Conferences)
... of Neuroendocrine Tumors (NETs) using Peptide Receptor RadioNuclide Thearpy (PRRNT).  The event was orginized by Prof. Dr. Richard P. Baum of Zentralklink, Bad Berka and Prof. Dr. Frank Rösch of the Institute  ...
Created on 08 September 2011
14. Steve Jobs resigns from Apple
(In the News)
Aug 24, 2011 - Steve Jobs - Apple's CEO resigned today saying he "could no longer meet my duties and expectations as Apple's CEO'.  Mr. Jobs has been battling pancreatic neuroendocrine cancer since 2004  ...
Created on 25 August 2011
15. CCAN NET Cancer Patients Conference Long Island
(Past Conferences )
... s included several local oncolgists, as well as Dr, O'Dorisio from Iowa,  Dr. Delpassand from Excel Diagnostics in Houston.and Leigh Anne Burns from Ochsner Kenner's Neuroendocrine Program.  It was a  ...
Created on 20 August 2011
16. Images from the 1st World Congress on GA-68 and PRRNT
(In the News)
... for individuals with Neuroendocrine tumors as well as other diseases that can be imaged with GA68. Please enjoy the photo gallery below. Viewing on an iPhone, iPad or other device that does not support ...
Created on 24 June 2011
17. Road to Basel - Terry Y.
(Basel)
... dd another perspective as I prepared for and conducted the trip myself as a patient in May and July, 2009. Baseline Requirements My Diagnosis: Since each person displays their neuroendocrine can ...
Created on 12 June 2011
18. Recently Published Articles
(Publications)
... eceptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011 May 31. [Epub ahead of print] PubMed PMID: 21626438. 2: Kolenc-Peitl P, Mansi R, Tamma M, Gmeiner-Stopar T, Sollner-Dolenc M, Waser  ...
Created on 11 June 2011
19. JCO Article on PRRT shows significantly improved overall survival rates.
(In the News)
Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers. Published in Journal of Clinical Oncology,  ...
Created on 27 May 2011
20. Jim M.
(Bad Berka)
It was in September of 2010 when I finally decided to have PRRT. It had been 5 years, almost to the day, since my original diagnosis with Stage 4 NeuroEndocrine Cancer, A.K.A. Carcinoid. I knew quite ...
Created on 22 April 2011